M108 omalizumab for chronic urticaria in an iga deficient patient

IgA deficiency is the most common primary immunodeficiency with patients developing recurrent sino-pulmonary infections, but limited data exists regarding if omalizumab is safe for patients with IgA deficiency. Known restrictions include blood products that contain IgA due to concern of anti-IgA mediated anaphylactic reaction. Here we present a patient with IgA deficiency and chronic urticaria that improved with omalizumab treatment.

Source: Annals of Allergy, Asthma and Immunology - October 31, 2019 Category: Allergy & Immunology Authors: F. Osman, R. Dass, K. Dass Source Type: research